BGM vs BioHarvest Sciences
BGM and BHST side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BGM and BHST compare
BGM grew revenue faster over the last twelve months (51.1% versus 37.0% for BioHarvest Sciences).
BioHarvest Sciences keeps more of each dollar of sales as profit, with a net margin of −32.3% compared with −52.6% at BGM.
BGM scores higher on the StockData Score (9 against 5 for BioHarvest Sciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BGM | BHST |
|---|---|---|
| Size and price | ||
| Share price | $7.88 | $1.50 |
| Change, 1 year | −97.2% | −80.9% |
| Change, 5 years | −98.4% | −86.1% |
| Beta (5Y) | 0.27 | 0.87 |
| Employees | 206 | – |
| StockData Score | ||
| Total score | 9 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 2 | 2 |
| Performance score | 2 (better) | 1 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 51.1% (better) | 37.0% |
| Revenue growth, 5Y average | −5.4% | – |
| Profitability | ||
| Gross margin | 16.6% | 59.3% (better) |
| Operating margin | −33.2% | −16.2% (better) |
| Net margin | −52.6% | −32.3% (better) |
| FCF margin | −10.4% (better) | −27.8% |
| Return on equity | −9.2% (better) | −83.2% |
| Return on invested capital | −4.8% (better) | −163% |
| Financial health | ||
| Debt / equity | 0.00 | 0.01 (better) |
| Current ratio | 1.24 | 3.97 (better) |
| Piotroski F-score | 4 | 5 (better) |
| Ownership | ||
| Held by institutions | 0.00% | 7.4% |
| Held by insiders | 52.5% | 0.00% |
| Short interest, % of float | 0.00% | 0.33% |
Go deeper
- BGM stock overview
- BGM income statement
- BGM valuation and score
- BHST stock overview
- BHST income statement
- BHST valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.